ResearcherNanjing Drum Tower HospitalActive in the last 2 years

B R Liu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5086435640. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2024: 1 paper

Papers 1

[A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. Last author DOI 10.3760/cma.j.cn112152-20231223-00383 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Huizi Sha · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗
Juan Du · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗
Hua Jiang · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗
Xin Qiu · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗
Jun Wu · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗
Qiao-Li Wang · 1 shared paper, 2024 · strength 0.15
- Paper [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. DOI 10.3760/cma.j.cn112152-20231223-00383 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.